Affimed to price IPO of 6.25 million shares between $11.00 and $13.00

Jefferies, Leerink and BMO to be joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Sept. 11 – Affimed Therapeutics BV will sell 6.25 million common shares in its initial public offering with a 30-day greenshoe option of 937,500 additional shares, according to a Form F-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced June 27.

The shares will be sold at a price expected to fall between $11.00 and $13.00 per share.

Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunning managers. Trout Capital is the co-manager.

Proceeds will be used for research and development activities, working capital, repayment of debt and general corporate purposes.

The biopharmaceutical company is based in Heidelberg, Germany. The company intends to list its common stock on the Nasdaq under the symbol “AFMD.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.